title: Raccoon dog rabies surveillance and post-vaccination monitoring in Lithuania 2006 to 2010.
abstract: BACKGROUND
  Oral rabies vaccination (ORV) in rabies infected regions should target the primary rabies vector species, which in Lithuania includes raccoon dogs as well as red foxes. Specific investigations on ORV in raccoon dogs are needed e.g. evaluation of vaccine effectiveness under field conditions. The objective of the current study was to investigate the efficacy of the ORV programme 2006-2010 in Lithuania by examining the number of rabies cases and estimating the prevalences of a tetracycline biomarker (TTC) and rabies virus antibodies in raccoon dogs.
  
  
  METHODS
  From 2006 to 2010, 12.5 million rabies vaccine-baits were distributed by aircraft. Baiting occurred twice per year (spring and autumn), targeting raccoon dogs and red foxes in a 63,000 km2 area of Lithuania. The mandibles of raccoon dogs found dead or killed in the vaccination area were analyzed by fluorescence microscopy for the presence of the TTC. Rabies virus sera neutralizing anti-glycoprotein antibody titres were determined using an indirect ELISA method and seroconversion (> 0.5 EU/ml) rates were estimated.
  
  
  RESULTS
  During the study period, 51.5% of raccoon dog mandibles were positive for TTC. 1688 of 3260 tested adults and 69 of 175 tested cubs were TTC positive. Forty-seven percent of raccoon dog serum samples were positive for rabies virus antibodies. 302 of 621 investigated adults and 33 of 95 investigated cubs were seropositive. In the same time 302 of 684 and 43 of 124 tested samples were TTC and ELISA positive in spring; whereas 1455 of 2751 and 292 of 592 tested samples were TTC and ELISA positive in autumn. There was a positive correlation between the number of TTC and antibody positive animals for both adult and cub groups.
  
  
  CONCLUSIONS
  ORV was effective in reducing the prevalence of rabies in the raccoon dog population in Lithuania. The prevalence of rabies cases in raccoon dogs in Lithuania decreased from 60.7% in 2006-2007 to 6.5% in 2009-2010.
authors.affiliation: Lithuanian University of Health Sciences, Veterinary Academy, Veterinary Institute, Tilzes 18, Kaunas, Lithuania. zienius@lva.lt
authors.forename: Dainius
authors.initials: D
authors.lastname: Zienius
authors.forename: Gediminas
authors.initials: G
authors.lastname: Pridotkas
authors.forename: Raimundas
authors.initials: R
authors.lastname: Lelesius
authors.forename: Vilimas
authors.initials: V
authors.lastname: Sereika
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D015415:Biomarkers / Q000097:blood; D005589:Foxes; D017589:Immunization Programs; D008097:Lithuania / Q000453:epidemiology; D011159:Population Surveillance; D015995:Prevalence; D015397:Program Evaluation; D011818:Rabies / Q000453:epidemiology / Q000517:prevention & control / Q000662:veterinary*; D011819:Rabies Vaccines / Q000276:immunology*; D011820:Rabies virus / Q000276:immunology / Q000302:isolation & purification; D046031:Raccoon Dogs / Q000097:blood / Q000276:immunology / Q000821:virology*; D013752:Tetracycline / Q000097:blood; D014611:Vaccination / Q000662:veterinary*
chemical_list: D000914:Antibodies, Viral; D015415:Biomarkers; D011819:Rabies Vaccines; D013752:Tetracycline
references.citation: Vaccine. 2003 Jun 20;21(21-22):2986-93
references.pmid: 12798642
references.citation: Acta Vet Hung. 2001;49(3):285-90
references.pmid: 11702339
references.citation: Dev Biol (Basel). 2006;125:59-68
references.pmid: 16878461
references.citation: J Immunol Methods. 2007 Jan 10;318(1-2):1-10
references.pmid: 17166510
references.citation: Biologicals. 2008 Jan;36(1):19-26
references.pmid: 17981476
references.citation: Rev Sci Tech. 2007 Dec;26(3):577-84
references.pmid: 18293606
references.citation: Vaccine. 2006 May 15;24(20):4386-92
references.pmid: 16603277
references.citation: Acta Vet Hung. 2001;49(3):291-4
references.pmid: 11702340
references.citation: Dev Biol (Basel). 2008;131:3-15
references.pmid: 18634461
references.citation: Dev Biol (Basel). 2008;131:239-47
references.pmid: 18634485
references.citation: J Gen Virol. 1992 May;73 ( Pt 5):1149-58
references.pmid: 1588319
references.citation: Dev Biol (Basel). 2006;125:145-7
references.pmid: 16878472
references.citation: Vaccine. 2001 Aug 14;19(31):4511-8
references.pmid: 11483278
references.citation: Vaccine. 2000 Aug 1;18(28):3272-9
references.pmid: 10869772
references.citation: Dev Biol (Basel). 2006;125:17-28
references.pmid: 16878456
references.citation: Dev Biol (Basel). 2008;131:213-22
references.pmid: 18634482
references.citation: Vet Res. 1999 Jul-Aug;30(4):353-62
references.pmid: 10478416
references.citation: Dev Biol (Basel). 2008;131:27-35
references.pmid: 18634463
references.citation: J Vet Med B Infect Dis Vet Public Health. 2003 May;50(4):204-6
references.pmid: 12916696
references.citation: Stat Med. 2007 Aug 30;26(19):3661-75
references.pmid: 17315184
references.citation: Dev Biol (Basel). 2006;125:119-26
references.pmid: 16878468
references.citation: Vaccine. 2007 Apr 30;25(17):3409-18
references.pmid: 17224221
references.citation: World Health Organ Tech Rep Ser. 2005;931:1-88, back cover
references.pmid: 16485446
references.citation: Arch Virol. 2005 Jul;150(7):1407-14
references.pmid: 15789260
references.citation: Vaccine. 2008 Aug 26;26(36):4627-38
references.pmid: 18620017
references.citation: Vet Rec. 1990 Aug 18;127(7):165-7
references.pmid: 2219648